Research Corporation Technologies Demonstrates A Hundred-Fold Improvement In Penetration Of Solid Tumors Using Therapeutic ABDURINS Compared To Antibodies

TUCSON, Ariz.--(BUSINESS WIRE)--Research Corporation Technologies (RCT) and collaborators have demonstrated that the small size and long half-life of ABDURIN binders targeting EphA2 on cancer cells leads to a 50- to 150-fold increase in penetration and accumulation into tumors compared to antibodies binding the same target.

Help employers find you! Check out all the jobs and post your resume.